Underwriters Exercise Over-allotment Option on Cancer Genetics IPO | GenomeWeb

NEW YORK (GenomeWeb News) – Cancer Genetics said after the close of the market on Friday that the underwriters of its initial public offering have exercised in full their over-allotment option to purchase 90,000 additional shares of its stock at $10 per share.

As a result, the total gross proceeds from the offering are expected to be $6.9 million, Cancer Genetics said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.